Why cancer drugs lose their power: Platinum-based cancer drugs destroy tumor cells by binding to DNA strands

April 14, 2010 by Anne Trafton, Massachusetts Institute of Technology
A 3-D model of a cisplatin molecule.

(PhysOrg.com) -- For 30 years, the chemotherapy drug cisplatin has been one of doctors' first lines of defense against tumors, especially those of the lung, ovary and testes. While cisplatin is often effective when first given, it has a major drawback: Tumors can become resistant to the drug and start growing again.

Now, MIT cancer biologists have shown how that resistance arises, a finding that could help researchers design new drugs that overcome cisplatin resistance. The team, led by Tyler Jacks, director of the David H. Koch Institute for Integrative Cancer Research at MIT, reports the results in the April 15 issue of the journal Genes and Development.

Cisplatin and other platinum-based cancer drugs destroy tumor cells by binding to DNA strands, interfering with DNA replication. That activates the cell’s DNA repair mechanisms, but if the damage is too extensive to be repaired, the cell undergoes programmed suicide.

Eventually, cancer cells learn to fight back. The new study shows that tumor cells treated with cisplatin ramp up their DNA repair pathways, allowing them to evade cell death, says Trudy Oliver, a postdoctoral fellow in Jacks’ lab and lead author of the paper.

Previous studies had suggested several possible mechanisms for resistance development, including enhancement of DNA repair pathways, detoxification of the drug, and changes in how the drug is imported into or exported out of the cell. However, those studies were done in cancer cells grown in the lab, not in living animals (in vivo).

“Many mechanisms have been identified but it’s not clear what happens in vivo because the in vivo environment is so much more complicated than in cell lines,” says Oliver.

Oliver and her colleagues set out to study cisplatin resistance in mice with a mutation in a gene called Kras, which leads the animals to develop lung cancer. About 30 percent of human lung cancer patients have mutations in Kras. Some of the mice also had defective versions of the tumor suppressor gene p53, which is mutated in about half of human lung cancers.

The researchers found that cisplatin was effective against lung tumors in both sets of mice, though it was more potent in mice that still had functional p53. In those mice, tumors actually shrank, while the drug only slowed tumor growth in mice with defective p53. Those results are consistent with findings in human patients.

After four doses of cisplatin, mice with normal p53 developed resistance to the drug, and tumors started growing faster. To figure out why, the researchers analyzed which genes were being transcribed more as resistance developed, and identified several that are involved in DNA repair pathways.

One gene that particularly caught the researchers’ attention is PIDD (p53-induced protein with a death domain), which is turned on by p53 and has been implicated in programmed cell death, though its exact function is not known. When PIDD levels are artificially increased in human lung cancer cells, they become more resistant to cisplatin. Oliver is now studying tumors in which the PIDD gene has been knocked out, to see if its absence hinders drug resistance.

It is likely that PIDD is just one of many genes, in many pathways, involved in the drug resistance process, says Oliver. “It’s not a simple phenomenon,” she says.

The work was funded by the National Institutes of Health and the National Cancer Institute.

This study represents an important step toward better understanding of how cisplatin resistance arises, says Thomas Helleday, professor of radiation oncology at the University of Oxford, who was not involved in the research. Helleday describes the work as a “landmark” paper that “has important implications in the design of new drugs, which should be targeted to stop the repair that is activated in cisplatin-resistant tumors.”

More information: "Chronic cisplatin treatment promotes enhanced damage repair and tumor progression in a mouse model of lung cancer," Trudy Oliver, Kim Mercer, Leanne Sayles, James Burke, Diana Mendus, Katherine Lovejoy, Mei-Hsin Cheng, Aravind Subramanian, David Mu, Scott Powers, Denise Crowley, Roderick Bronson, Charles Whittaker, Arjun Bhutkar, Stephen Lippard, Todd Golub, Juergen Thomale, Tyler Jacks and Alejandro Sweet-Cordero; Genes and Development.

Related Stories

Recommended for you

Key differences in young, older people's immune cells attributed to environment

April 26, 2018
Discoveries by Stanford University School of Medicine investigators may help explain why older people's immune systems often don't work so well, why different people's immune systems age at different rates, and why the environment ...

Unprecedented study identifies 44 genetic risk factors for major depression

April 26, 2018
A global research project has mapped out the genetic basis of major depression, identifying 44 genetic variants which are risk factors for depression, 30 of which are newly discovered. The study, by the Psychiatric Genomics ...

New testing provides better information for parents of children with form of epilepsy

April 26, 2018
Advances in genetic testing offer new insights to parents who have a child with a rare but serious form of epilepsy, epileptic encephalopathy (EE), found in one of about every 2,000 births and characterized by developmental ...

Natural barcodes enable better cell tracking

April 24, 2018
Each of us carries in our genomes about 10 million genetic variations called single nucleotide polymorphisms (SNPs), which represent a difference of just one letter in the genetic code. Every human's pattern of SNPs is unique ...

The role of 'extra' DNA in cancer evolution and therapy resistance

April 23, 2018
Glioblastoma (GBM) is the most common and aggressive form of brain cancer. Response to standard-of-care treatment is poor, with a two-year survival rate of only 15 percent. Research is beginning to provide a better understanding ...

Variants in non-coding DNA contribute to inherited autism risk

April 19, 2018
In recent years, researchers have firmly established that gene mutations appearing for the first time, called de novo mutations, contribute to approximately one-third of cases of autism spectrum disorder (ASD). In a new study, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.